Clinical Trial Update: Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

DT-7012 is being studied as a single agent and in combination with an immune checkpoint inhibitor in a Phase 1/2 trial for advanced solid tumors. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• DT-7012

Snippet

Sponsor: Domain Therapeutics Australia Pty Ltd | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING